What Plasma Can Tell Us When Tissue Cannot: A Case Report of Genomic Testing in mCRPC and Clinical Response to Treatment With the PARP Inhibitor Rucaparib

BACKGROUND: The poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib was approved in the United States based on the phase 2 TRITON2 study of patients with BRCA1 or BRCA2 (BRCA)–mutated metastatic castration-resistant prostate cancer (mCRPC). Although genomic screening is recommended as part of a c...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrylak, Daniel P., Watkins, Simon P., Loehr, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377337/
https://www.ncbi.nlm.nih.gov/pubmed/35978838
http://dx.doi.org/10.3389/fonc.2022.951348

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377337/
https://www.ncbi.nlm.nih.gov/pubmed/35978838
http://dx.doi.org/10.3389/fonc.2022.951348

Ejemplares similares